通过招募ATF4,PTX促进乳腺癌的迁移和入侵,以提高FGF19的调节
Ting Xue1, Xuezhen Wang1, Xianjun Pan2
1School of Medicine, Chongqing University, Chongqing 400044, People's Republic of China.
Cellular signalling
|July 25, 2024
概括
化疗药物帕克利塔塞尔通过ATF4调节FGF19表达来增加乳腺癌细胞的迁移和入侵. 这一途径突出了乳腺癌患者化疗诱导转移的潜在机制.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 乳腺癌是妇女死亡的主要原因,化疗是主要治疗方法.
- 一些化疗药物,特别是帕克利塔塞尔,可以矛盾地促进瘤转移.
- 了解化学疗法诱导的转移背后的分子机制对于改善患者的治疗结果至关重要.
研究的目的:
- 研究FGF19及其信号通路在帕克利塔塞尔诱导的乳腺癌细胞迁移和入侵中的作用.
- 阐明帕克利塔塞尔影响乳腺癌进展的分子机制.
- 在接受化疗的乳腺癌患者中分析FGF19表达的临床意义.
主要方法:
- 在化疗前后的临床乳腺癌组织中分析FGF19表达.
- 实验室试验 (CCK8,Transwell,Western blot,qRT-PCR,免疫光) 来评估帕克利塔塞尔,FGF19和ATF4对乳腺癌细胞的影响.
- 在裸体小鼠的体内肺转移模型中,确认了帕克利塔塞尔和FGF19.19的影响.
主要成果:
- 帕克利塔克塞尔治疗增加了乳腺癌细胞迁移和入侵,与FGF19表达率升高相关.
- 乳腺癌患者的FGF19表达在化疗后被上调.
- 该研究确定了ATF4在调解FGF19增强的乳腺癌细胞迁移中的潜在作用,这与帕克利塔塞尔诱导的应激反应有关.
结论:
- 帕克利塔塞尔促进乳腺癌细胞迁移和入侵,通过ATF4通道上调FGF19表达.
- 这种机制为了解化疗如何导致乳腺癌转移提供了洞察力.
- 针对FGF19/ATF4轴可能提供新的治疗策略,以减轻化疗诱导的转移.
更多相关视频
相关概念视频
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Cancer Cell Migration through Invadopodia
2.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K


